News & Updates

Urine test predicts bladder cancer risk 12 years prior to symptom onset

24 Apr 2023 by

A simple urine test looking at genetic mutations in DNA predicts urothelial cancer – the most common type of bladder cancer – 12 years before patients develop symptoms in a recent study.

Urine test predicts bladder cancer risk 12 years prior to symptom onset

24 Apr 2023

Pembrolizumab plus chemo improves PFS in endometrial cancer regardless of MMR status

22 Apr 2023 by

The addition of pembrolizumab to standard chemotherapy significantly improves progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, regardless of whether they had mismatch repair-deficient (dMMR) or mismatch repair-proficient (pMMR) disease, according to the NRG-GY018 trial presented at the SGO 2023.

Pembrolizumab plus chemo improves PFS in endometrial cancer regardless of MMR status

22 Apr 2023

Tremelimumab delivers linear pharmacokinetics in patients with advanced solid tumours

20 Apr 2023

A linear pharmacokinetics characterizes tremelimumab, a cytotoxic T-lymphocyte-associated protein 4 human monoclonal antibody of the immunoglobulin G2 κ isotype, in patients with advanced solid tumours, reveals a study.

Tremelimumab delivers linear pharmacokinetics in patients with advanced solid tumours

20 Apr 2023

Is supracervical better than total hysterectomy during colorectal resection?

20 Apr 2023 by

Undergoing supracervical hysterectomy during colorectal resection seems to reduce the duration of the procedure, the need for blood transfusion, as well as the length of hospital stay, according to a study presented at the 2023 SGO Annual Meeting on Women’s Cancer.

Is supracervical better than total hysterectomy during colorectal resection?

20 Apr 2023

Can an antibody-drug conjugate alter the treatment landscape of difficult-to-treat ovarian cancer?

20 Apr 2023 by

Mirvetuximab soravtansine (MIRV), an antibody drug conjugate (ADC), showed antitumour activity in women with platinum-resistant ovarian cancer* (PROC) with high folate receptor alpha (FRα) expression, findings from the phase III SORAYA study have shown.

Can an antibody-drug conjugate alter the treatment landscape of difficult-to-treat ovarian cancer?

20 Apr 2023

Advanced disease, recurrence precede brain metastasis from gynaecologic cancers

19 Apr 2023 by

Patients with brain metastasis from gynaecologic cancers often present with an advanced stage disease and have had at least one prior recurrence, according to a study. In addition, the presence of an extracranial disease is common at the time of brain metastasis diagnosis.

Advanced disease, recurrence precede brain metastasis from gynaecologic cancers

19 Apr 2023

Maximal transurethral resection tied to better outcomes at cystectomy

19 Apr 2023

Pathological response at cystectomy may improve with maximal resection in patients undergoing transurethral resection for muscle-invasive bladder cancer prior to neoadjuvant chemotherapy, according to a study.

Maximal transurethral resection tied to better outcomes at cystectomy

19 Apr 2023

Add-on dostarlimab boosts PFS in endometrial cancer

19 Apr 2023 by

Adding dostarlimab, an immune checkpoint inhibitor, to standard-of-care chemotherapy significantly improves progression-free survival (PFS) in patients with primary advanced or recurrent endometrial cancer, including those with dMMR-MSI-H* disease, according to the first interim analysis of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial presented at SGO 2023.

Add-on dostarlimab boosts PFS in endometrial cancer

19 Apr 2023

Mitomycin gel safe, effective after complete endoscopy of urothelial carcinoma

18 Apr 2023

Maximal endoscopic ablation prior to treatment with reverse thermal polymer gel of mitomycin C (UGN-101) treatment appears to lead to fewer patients with upper tract urothelial carcinoma at first endoscopy and fewer adverse events (AEs) when compared with primary chemoablative therapy, suggests a recent study.

Mitomycin gel safe, effective after complete endoscopy of urothelial carcinoma

18 Apr 2023

A win for gemcitabine plus cisplatin and intensity-modulated radiotherapy in vulvar cancer

17 Apr 2023 by

The use of gemcitabine concurrently with cisplatin and intensity-modulated radiation therapy appears to improve response and prolong progression-free survival in women with locally advanced vulvar cancer not amenable to surgical resection, according to the results of the phase II NRG Oncology Trial 279 (NRG-GOG-0279) presented at SGO 2023.

A win for gemcitabine plus cisplatin and intensity-modulated radiotherapy in vulvar cancer

17 Apr 2023

News & Updates

Filter by Specialty:

Specialty:

Urine test predicts bladder cancer risk 12 years prior to symptom onset

Urine test predicts bladder cancer risk 12 years prior to symptom onset

Pembrolizumab plus chemo improves PFS in endometrial cancer regardless of MMR status

Pembrolizumab plus chemo improves PFS in endometrial cancer regardless of MMR status

Tremelimumab delivers linear pharmacokinetics in patients with advanced solid tumours

Tremelimumab delivers linear pharmacokinetics in patients with advanced solid tumours

Is supracervical better than total hysterectomy during colorectal resection?

Is supracervical better than total hysterectomy during colorectal resection?

Can an antibody-drug conjugate alter the treatment landscape of difficult-to-treat ovarian cancer?

Can an antibody-drug conjugate alter the treatment landscape of difficult-to-treat ovarian cancer?

Advanced disease, recurrence precede brain metastasis from gynaecologic cancers

Advanced disease, recurrence precede brain metastasis from gynaecologic cancers

Maximal transurethral resection tied to better outcomes at cystectomy

Maximal transurethral resection tied to better outcomes at cystectomy

Add-on dostarlimab boosts PFS in endometrial cancer

Add-on dostarlimab boosts PFS in endometrial cancer

Mitomycin gel safe, effective after complete endoscopy of urothelial carcinoma

Mitomycin gel safe, effective after complete endoscopy of urothelial carcinoma

A win for gemcitabine plus cisplatin and intensity-modulated radiotherapy in vulvar cancer

A win for gemcitabine plus cisplatin and intensity-modulated radiotherapy in vulvar cancer